NASDAQ$ALEC
Alector Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Alector reported its Q4 and full year 2021 financial results, highlighting clinical and preclinical pipeline advancements and a strong cash position.
Alector reported Q4 2021 collaboration revenue of $14.0 million compared to $4.9 million for the same period in 2020. The company's cash, cash equivalents, and investments totaled $735.3 million as of December 31, 2021. Alector anticipates existing funds will support operations into mid-2024.
- Collaboration revenue increased to $14.0 million for the quarter ended December 31, 2021, compared to $4.9 million for the same period in 2020.
- Total research and development expenses were $52.8 million for the quarter ended December 31, 2021, compared to $44.4 million for the quarter ended December 31, 2020.
- Net loss for the quarter ended December 31, 2021, was $55.6 million, or $0.68 per share, compared to a net loss of $52.2 million, or $0.66 per share, for the same period in 2020.
- Cash, cash equivalents, and marketable securities were $735.3 million as of December 31, 2021.
Headline financials
Revenue & EPS history
Alector · Revenue · Quarterly
$14M
Revenue by segment
Alector · $14M total across 1 segment · Q4 2021
- Collaboration Revenue$14M+188.5%100.0%
Forward guidance
Alector anticipates that the company’s existing cash, cash equivalents, and marketable securities, including the net proceeds received from GSK in January 2022, are sufficient to fund projected operations into mid-2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.1%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-5.5%
Avg return
30 days after
52%
15 / 29 earnings
Positive
+32.9%
Q2 2023
Best reaction
-18.4%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -16.0% | -36.6% | |
| Q4 2025 | +7.1% | -11.7% | -16.3% | |
| Q3 2025 | +4.1% | +8.4% | -2.8% | |
| Q1 2025 | +4.2% | +7.4% | +23.8% | |
| Q4 2024 | -3.5% | -15.4% | -25.0% | |
| Q3 2024 | +12.8% | +21.3% | -56.8% | |
| Q2 2024 | +0.8% | +0.9% | -4.2% | |
| Q1 2024 | -1.9% | +1.7% | -17.7% | |
| Q4 2023 | +7.9% | +14.4% | -7.1% | |
| Q3 2023 | -2.6% | -17.7% | +6.0% | |
| Q2 2023 | +32.9% | +12.4% | -15.6% | |
| Q1 2023 | +13.0% | +20.6% | +8.5% | |
| Q4 2022 | +0.9% | -9.5% | -30.3% | |
| Q3 2022 | -18.4% | +3.1% | +3.1% | |
| Q2 2022 | +16.3% | +12.7% | -6.9% | |
| Q1 2022 | -12.7% | -20.0% | -11.9% | |
| Q4 2021 | +1.9% | -1.3% | -7.8% | |
| Q3 2021 | +2.3% | +4.1% | -20.7% | |
| Q2 2021 | +9.5% | +9.0% | +10.1% | |
| Q1 2021 | -7.8% | -12.4% | +6.1% | |
| Q4 2020 | -4.7% | -10.7% | -14.3% | |
| Q3 2020 | +0.4% | +7.2% | +25.2% | |
| Q2 2020 | -6.9% | -7.4% | -13.5% | |
| Q1 2020 | -5.0% | +0.3% | +3.7% | |
| Q4 2019 | -1.5% | -4.4% | +0.8% | |
| Q3 2019 | -6.1% | -4.2% | +19.5% | |
| Q2 2019 | -1.7% | -18.0% | +9.4% | |
| Q1 2019 | +4.9% | +1.3% | +0.2% | |
| Q4 2018 | -8.6% | -3.5% | +10.8% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro